Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis.

Next Previous
Trial Profile

Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Antithymocyte globulin; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus
  • Indications Allotransplant rejection; Graft-versus-host disease
  • Focus Therapeutic Use

Most Recent Events

  • 01 May 2018 Status changed from recruiting to completed.
  • 07 Mar 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.
  • 16 Apr 2012 Planned end date changed from 1 Dec 2014 to 1 Sep 2017 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top